Health Care & Life Sciences » Biotechnology | Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
89,225.00
360,395.00
290,073.00
410,108.00
490,874.00
761,497
Depreciation, Depletion & Amortization
10,229.00
11,926.00
19,050.00
15,130.00
13,367.00
6,435
Other Funds
18,457.00
212,229.00
46,767.00
70,058.00
97,623.00
147,347
Funds from Operations
60,539.00
136,240.00
224,256.00
324,920.00
379,884.00
607,715
Changes in Working Capital
8,118.00
29,401.00
35,116.00
17,219.00
2,902.00
45,099
Net Operating Cash Flow
68,657.00
165,641.00
189,140.00
307,701.00
382,786.00
562,616
Capital Expenditures
4,006.00
8,961.00
12,950.00
64,557.00
104,209.00
Purchase/Sale of Investments
126,499.00
514,853.00
308,371.00
207,148.00
186,152.00
Net Investing Cash Flow
130,505.00
548,814.00
321,321.00
142,591.00
290,361.00
Issuance/Reduction of Debt, Net
-
-
-
150,000.00
120,000.00
Net Financing Cash Flow
200,926.00
736,465.00
616,177.00
177,832.00
1,124,891.00
Net Change in Cash
1,764.00
22,010.00
105,716.00
12,722.00
451,744.00
Free Cash Flow
72,663.00
174,602.00
202,090.00
372,258.00
486,995.00
Net Assets from Acquisitions
-
25,000.00
-
-
-
Change in Capital Stock
200,926.00
736,465.00
616,177.00
27,832.00
1,244,891.00

About Alnylam Pharmaceuticals

View Profile
Address
300 Third Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.alnylam.com
Updated 07/08/2019
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.